Orion Portfolio Solutions LLC Buys 73,758 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Orion Portfolio Solutions LLC lifted its stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 359.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 94,282 shares of the company’s stock after buying an additional 73,758 shares during the period. Orion Portfolio Solutions LLC’s holdings in Dr. Reddy’s Laboratories were worth $1,489,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. raised its holdings in Dr. Reddy’s Laboratories by 453.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after acquiring an additional 9,373,412 shares in the last quarter. Van ECK Associates Corp raised its stake in shares of Dr. Reddy’s Laboratories by 609.4% in the fourth quarter. Van ECK Associates Corp now owns 5,838 shares of the company’s stock valued at $92,000 after purchasing an additional 5,015 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Dr. Reddy’s Laboratories by 400.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company’s stock worth $8,373,000 after purchasing an additional 427,573 shares during the period. World Investment Advisors LLC acquired a new stake in Dr. Reddy’s Laboratories during the third quarter worth $3,459,000. Finally, Crossmark Global Holdings Inc. increased its holdings in Dr. Reddy’s Laboratories by 328.3% in the 4th quarter. Crossmark Global Holdings Inc. now owns 12,760 shares of the company’s stock valued at $201,000 after buying an additional 9,781 shares during the period. 3.85% of the stock is owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Stock Performance

Shares of NYSE:RDY opened at $13.24 on Friday. The stock has a market capitalization of $11.05 billion, a price-to-earnings ratio of 21.07 and a beta of 0.48. The business’s fifty day moving average price is $13.36 and its two-hundred day moving average price is $14.54. Dr. Reddy’s Laboratories Limited has a fifty-two week low of $12.50 and a fifty-two week high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, analysts predict that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on RDY shares. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.